Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y5K1
UPID:
SPO11_HUMAN
Alternative names:
Cancer/testis antigen 35
Alternative UPACC:
Q9Y5K1; Q5TCI1; Q8N4V0; Q9NQM7; Q9NQM8
Background:
Meiotic recombination protein SPO11, also known as Cancer/testis antigen 35, plays a pivotal role in meiotic recombination. It forms a complex with TOP6BL, essential for DNA cleavage that initiates meiotic recombination, facilitating the relaxation and decatenation of supercoiled DNA through cleavage and ligation cycles. It is crucial for the phosphorylation of proteins such as SMC3, HORMAD1, and HORMAD2.
Therapeutic significance:
Understanding the role of Meiotic recombination protein SPO11 could open doors to potential therapeutic strategies.